Pressemitteilungen der CVC Group


  • Jedes Wort
  • Alle Wörter
  • Exakter Ausdruck
Date:Thursday 12 October 2017
Title:CVC Capital Partners’ Strategic Opportunities platform and Téthys Invest enter into exclusive negotiations to acquire majority stake in Sebia

CVC Capital Partners’ Strategic Opportunities platform and Téthys Invest enter into exclusive negotiations to acquire majority stake in Sebia

CVC Capital Partners Strategic Opportunities (“CVC”) and Téthys Invest today announced that they have entered into final exclusive negotiations with respect to the acquisition of Astorg and Montagu Private Equity’s remaining majority stake in Sebia. CVC and Téthys Invest would therefore join Caisse de dépôt et placement du Québec (“CDPQ”) and Sebia management as shareholders of Sebia.

Founded in 1967, Sebia is a world leading provider of clinical protein electrophoresis equipment and reagents, a technology used for in-vitro diagnostic testing. Its systems analyse proteins in order to screen and monitor various diseases and conditions; primarily oncology (Multiple Myeloma), metabolic disorders such as Diabetes and also Hemoglobinopathy and rare pathologies. The company is headquartered in Lisses, France, and operates across more than 120 countries.

Benoît Adelus, Chairman of Sebia, commented: "I would like to thank both Astorg and Montagu teams for their strong support over the past three years. We welcome CVC and Téthys Invest as new shareholders of Sebia. Together with CDPQ and management, our new shareholders support our strategy and growth plans with a long term view. We look forward to reinforcing Sebia's franchise and expand its product and geographical footprint."

The contemplated transaction remains subject to workers' council information and consultation and to the approval of relevant regulatory authorities. The terms of the transaction were not disclosed.